Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$139.18M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 4.34M

Average 8.14M

Income Statement

Follow revenue through to earnings.

Revenue

$2.04M

FY 2025 · Annual

Operating Income

-$107.44M

FY 2025 · Annual

Net Income

-$40.83M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.26M1.57M002.04M
Cost of Revenue61.34M8.26M76.55M7.19M17.05M
Gross Profit(60.08M)(6.69M)(76.55M)(7.19M)(15.01M)
Gross Margin-4756.8%-427.5%——-736.5%
Research & Development61.34M63.26M76.55M88.6M69.3M
Selling, General & Admin21.13M22.88M20.39M25.8M31.17M
Operating Expenses21.13M77.89M23.5M107.21M92.43M
Depreciation & Amortization8.24M8.21M7.72M7.19M7.35M
EBITDA(13.89M)2.45M(96.46M)(132.23M)(22.24M)
EBITDA Margin-1099.6%156.2%——-1091.2%
Operating Income(81.21M)(84.58M)(100.05M)(114.4M)(107.44M)
Operating Margin-6429.8%-5404.3%——-5271.7%
Interest Income16K2.63M5.47M4.1M2.59M
Interest Expense4.35M6.2M6.6M9.28M11.25M
Other Income / Expenses54.73M72.61M(10.73M)(34.3M)66.6M
Income Before Tax(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Pre-Tax Margin-2096.4%-764.5%——-2003.6%
Income Tax Expense00000
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Net Margin-2096.4%-764.5%——-2003.6%
EPS (Basic)(0.66)(0.12)(1.07)(1.26)(0.26)
EPS (Diluted)(0.66)(0.12)(1.07)(1.26)(0.26)
Weighted Avg Shares39.97M103.05M103.42M118.48M158.16M
Weighted Avg Shares (Diluted)39.97M103.05M103.42M118.48M158.16M

HUMA Earnings Waterfall · TTM

NASDAQ:HUMA · Revenue to Net Income

Key Ratios

EPS$-0.59
Gross Margin-827.6%
Net Margin-5926.8%
P/E Ratio-2.3
P/S Ratio503.2

Analysis

$2.0M of revenue converted into -$97.6M of net income for the selected period. Gross margin is -827.6% and net margin is -5926.8%, showing how much revenue survives after costs and taxes. EPS is $-0.59, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 7, 2026
4Statement of changes in beneficial ownershipOct 7, 2026
3Initial statement of beneficial ownershipSep 28, 2026

How much revenue does HUMA generate?

Humacyte, Inc. (HUMA) reported $2.04M of revenue in fiscal 2025.

Is HUMA profitable?

Humacyte, Inc. (HUMA) reported -$40.83M of net income, with a net margin of -2003.6%.